Nucleoside analogues containing phosphonate or phosphonamide groups

• US 8,163,718 B2
• Filed: 02/19/2009
• Issued: 04/24/2012
• Est. Priority Date: 02/20/2008
• Status: Active Grant

• Current Assignee: Gilead Sciences Inc.
• Original Assignee: Gilead Sciences Inc.
• Inventors: Birkus, Gabriel, Ray, Adrian S., Tumas, Daniel B., Watkins, William J.
• Primary Examiner(s): BERCH, MARK L
• Application Number:
  US12/388,789
• Publication Number:
  US 20090232768A1
• Time in Patent Office: 1,160 Days
• Field of Search: 544/244, 514/81
• US Class Current: 514/81
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07F 9/65616 containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Abstract

Novel compounds having structure (1)

wherein Z, is N or CH to form a purine, Y, R¹, R^2′ and R² are defined in the specification, are provided for use in the treatment of tumors and the prophylaxis or treatment of viral infections.

Claims

1. A compound having structure (4)

5. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 1 and a carrier.

2. A compound having structure (5)

6. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 2 and a carrier.

3. A compound having structure (7):

7. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 3 and a carrier.

9. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 3 and a second therapeutic agent selected from an anti-viral agent or an anti-tumor/cancer agent.

4. A compound selected from the group consisting of:

8. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 4 and a carrier.

10. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to claim 4 and a second therapeutic agent selected from an anti-viral agent or an anti-tumor/cancer agent.